Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
Shanghai pulmonary hospital, Tongji University, Shanghai, Shanghai, China
CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, Shanghai, China
Hematology Center after prof. R. Yeolyan, Yerevan, Armenia
National Center of Oncology named after V.A. Fanarjian, Yerevan, Armenia
Optimum Research (Southwest Women's Oncology Center), Albuquerque, New Mexico, United States
Amphia Hospital, Breda, Netherlands
Medisch Spectrum Twente, Enschede, Netherlands
Tjongerschans Hospital, Heerenveen, Netherlands
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Lucille Packard Children's Hospital Stanford, Palo Alto, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta, Georgia, United States
Austin Health, Melbourne, Victoria, Australia
Medizinische Universitaet Wien, Vienna, Austria
Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria
Sahlgrenska östra sjukhuset, Gothenburg, Sweden
Skånes universitetssjukhus, Malmö, Sweden
Karolinska sjukhuset, Stockholm, Sweden
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Haukeland University Hospital, Bergen, Norway
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Cross Cancer Institute, Edmonton, Alberta, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.